Navigation Links
Delmarva Foundation Welcomes New Chief Operating Officer
Date:11/29/2007

Joy Hogan Rozman, RN, M.Ed., Assumes New Post

EASTON, Md., Nov. 29 /PRNewswire-USNewswire/ -- Delmarva Foundation for Medical Care announced recently that Joy Hogan Rozman, R.N., M.Ed., will serve as the company's new Chief Operating Officer. In this position, she will oversee three major areas of the Easton-based, non-profit healthcare consulting organization: performance assessment and validation; data integrity; and interventions. A senior executive with more than 20 years executive leadership and management experience, Ms. Rozman joined Delmarva on November 19.

"Throughout her career she has demonstrated the ability to achieve maximum performance and transformational change as a results-oriented, inspirational leader," commented Dr. Christian E. Jensen, Delmarva's President and CEO. "We know she will contribute greatly to our future growth."

Experienced in both the public and private sectors, Ms. Rozman has an extensive background in public health and human service settings in the United States and Europe including 19 years of QIO experience with the Virginia Health Quality Center (VHQC). As the Chief Executive Officer of VHQC for 11 years, she successfully led the organization through six non-competitive major contract renewals. Under her guidance, VHQC was an unprecedented three-time winner of the U.S. Senate Productivity and Quality Award for Virginia. Ms. Rozman is also the first--and only--Chief Executive Officer in the industry to be appointed to the Malcolm Baldrige National Quality Award Board of Examiners. She is the recipient of the 2004 Distinguished Executive Leadership Award from the James Q. Cannon Endowment for excellence in advancing the field of quality improvement.

Ms. Rozman previously served in several leadership roles as a Department of the Army civilian both in the Tidewater, Virginia area and in Germany, and a large multi-facility health system in Virginia Beach, Virginia.

Most rece
'/>"/>

SOURCE Delmarva Foundation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Delmarva Foundation Implements Medication Therapy Management Program in Maryland and DC
2. National Award Recognizes Delmarva Foundation and CareFirst BlueCross BlueShield Quality Improvement Efforts
3. Delmarva Foundation Announces 2007 Trustee Awardees
4. National Patient Safety Foundation Partners with Vocera Communications
5. R. P. Simmons Family Foundation Pledges $2 Million for New Childrens Hospital of Pittsburgh of UPMC Campus
6. Super Jake Foundation Offers Hope for Pediatric Cancer
7. The American Liver Foundation Appoints Rick Smith, a Twenty-Year Veteran of The MS Society, as Chief Executive Officer
8. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
9. AIDS Healthcare Foundation Applauds City Commissioners Support of Diversity, Urges Call for Mayors Resignation
10. National Osteoporosis Foundation Teams Up With Ladies Home Journal Magazine to Launch a 10-city Mall Walk Tour
11. Judge Rules That Florida Disease Management Program Serving 8,000 HIV/AIDS Patients Should Be Re-bid, Says AIDS Healthcare Foundation
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 2Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 3Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 4Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 2Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 3Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 2Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 3Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 4Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 5Childrens Hospitals and Clinics of Minnesota Launches H1N1 Outreach Effort with Minneapolis and Saint Paul Public Schools 58019 1Childrens Hospitals and Clinics of Minnesota Launches H1N1 Outreach Effort with Minneapolis and Saint Paul Public Schools 58019 2Childrens Hospitals and Clinics of Minnesota Launches H1N1 Outreach Effort with Minneapolis and Saint Paul Public Schools 58019 3Revolutionary Drug Could Be New Hope for Adrenal Cancer Patients 58017 1Revolutionary Drug Could Be New Hope for Adrenal Cancer Patients 58017 2Revolutionary Drug Could Be New Hope for Adrenal Cancer Patients 58017 3Revolutionary Drug Could Be New Hope for Adrenal Cancer Patients 58017 4Revolutionary Drug Could Be New Hope for Adrenal Cancer Patients 58017 5ScienceFirst Staff Expansion 58015 1
Other Medicine Technology:Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 2Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 3Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 4Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 5Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 7Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 8Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 9Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 10InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL) 2InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL) 3InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL) 4InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL) 5